ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Latest Information Update: 16 Aug 2022
At a glance
- Drugs SER 287 (Primary) ; Vancomycin
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms ECO-RESET
- Sponsors Seres Therapeutics
- 16 Dec 2021 Results presented in a Seres Therapeutics Media Release.
- 26 Oct 2021 Status changed from active, no longer recruiting to discontinued due to the lack of a clinical efficacy signal in the induction treatment phase. Seres closed the dosing phases of open label and maintenance portions of the study. Patients who had received prior doses were followed for safety data.
- 03 Aug 2021 According to a Seres Therapeutics media release, the company expects to obtain microbiome data in H2 2021.